Eisai, Nuvation Bio Announces European Medicines Agency Validate Marketing Authorisation Application For Taletrectinib To Treat ROS1-Positive Non-Small Cell Lung Cancer

Eisai Co., Ltd. and Nuvation Bio Inc. announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application for taletrectinib, aimed at treating advanced ROS1-positive non-small cell lung cancer. The application will undergo a standard review timeline. This development marks a significant step in the companies' efforts to address challenges in cancer treatment.